Who are Interleukin-3's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gm-Csf, IL-2 (interleukin 2), vunakizumab and recaticimab., Interleukin 2, Interferon beta 1a, oral doxycycline, vemurafenib + HD IL-2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/interleukin-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Interleukin-3 — Competitive Intelligence Brief

Interleukin-3 (Interleukin-3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine. Area: Hematology/Oncology.

marketed Cytokine IL-3 receptor (CD123) Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Interleukin-3 (Interleukin-3) — Sandoz. Interleukin-3 is a cytokine that stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells, promoting the production of multiple blood cell lineages.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Interleukin-3 TARGET	Interleukin-3	Sandoz	marketed	Cytokine	IL-3 receptor (CD123)
Gm-Csf	gm-csf	Pfizer	marketed	cytokine	GM-CSF receptor	1991-01-01
IL-2 (interleukin 2)	IL-2 (interleukin 2)	King's College London	marketed	Cytokine	IL-2 receptor (IL-2R)
vunakizumab and recaticimab.	vunakizumab and recaticimab.	Xiangya Hospital of Central South University	marketed	Monoclonal antibody (anti-cytokine)	IL-12/IL-23 p40 subunit (vunakizumab); TNF-α (recaticimab)
Interleukin 2	Interleukin 2	Assistance Publique - Hôpitaux de Paris	marketed	Cytokine immunotherapy	IL-2 receptor (CD25)
Interferon beta 1a, oral doxycycline	Interferon beta 1a, oral doxycycline	Louisiana State University Health Sciences Center Shreveport	marketed	Cytokine + tetracycline antibiotic combination	Interferon-beta receptor (IFNBR); doxycycline targets bacterial ribosomes and matrix metalloproteinases
vemurafenib + HD IL-2	vemurafenib + HD IL-2	Clinigen, Inc.	marketed	BRAF inhibitor + cytokine immunotherapy	BRAF V600E kinase; IL-2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine class)

Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Centre for Endocrinology and Reproductive Medicine, Italy · 1 drug in this class
Amgen · 1 drug in this class
Orasis Pharmaceuticals Ltd. · 1 drug in this class
Radboud University Medical Center · 1 drug in this class
Sandoz · 1 drug in this class
King's College London · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Interleukin-3 — Competitive Intelligence Brief. https://druglandscape.com/ci/interleukin-3. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab